Arca
Skip to content

AVT04: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761343's history or Alvotech USA's company page.

On Oct 11, 2023, FDA declined to approve AVT04 (BLA 761343) from Alvotech USA Inc. in its present form, citing facility inspections, product quality, microbial quality. The application was later approved.

  • Letter date: Oct 11, 2023
  • Application: BLA 761343
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspectionsProduct qualityMicrobial quality

The Letter

Text from openFDA

Following inspection of Alvotech hf, Reykjavik, Iceland (FEI: 3013702557) listed in this application, FDA conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be appr...… openFDA did not return the full text just now. Open it in the letter search.

Alvotech USA's Other Letters

Newest first
  • AVTO5Nov 26, 2025 · BLA 761461 · not approved
  • AVT06Nov 24, 2025 · BLA 761435 · not approved
  • AVTO5Oct 31, 2025 · BLA 761462 · not approved
  • AVTO2Jun 28, 2023 · BLA 761299 · later approved
  • AVT02Dec 20, 2022 · BLA 761299 · later approved

Record

Company
Alvotech USA Inc.
Application
BLA 761343
Status in openFDA
Approved
Review division
Division of Dermatology and Dentistry

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.